The Daily Telegraph in the UK has the latest on the vote from the FDA Advisory Panel to drop Avastin as an endorsed treatment for breast cancer patients. The drug prevented blood flow to the tumors, extending the amount of time before the disease worsened. However, now that the FDA Advisory Panel has dropped their endorsement because the drug may only extend lives by a month, possibly even less, US Insurers could possibly stop covering the drug in their health plans. They cited "cost effectiveness" was the reason their endorsement was dropped.
What are the long term effects this will have on healthcare coverage in the United States? What kind of implications could "Cost Effectiveness" have on future drugs and their coverage on healthcare plans?
About Us
Health Care Insights - From Policy to Practice is the trusted source for news and commentary from the nation's leading Health Care Events such as Medicaid Drug Rebate Program Summit (MDRP), Medicaid Managed Care Congress (MMCC), FDA/CMS to inform Health Plans and Pharmaceutical Manufacturers on the latest developments on Medicare, Medicaid Managed Care, Government Programs, and Health Insurance Exchanges.
Topics we cover include reform, best business practices, the latest innovations, and novel payment models.
Subscribe
Blog Archive
-
▼
2010
(111)
-
▼
August
(14)
- HealthSpring becomes 7th largest Medicare Advantag...
- Seniors will see a gap closing in the doughnut hole
- Some physicians leaving Medicare due to costs
- What effect will Avastin's fate have on healthcare?
- Pharma and Health Plan executives debate criteria ...
- MDRP 2010: Attending Companies to Date
- Overspending on many drugs in Medicaid
- Doctors not taking full advantage of ePrescribing
- IIR Announces Healthcare Reform Forum Program, Dat...
- Missouri votes against part of health care reform
- Medicare funds should be extended
- White Paper: Pharmaceutical Marketing in Perspecti...
- ePrescribing among physicians is limited
- Obama administration sees savings in healthcare now
-
▼
August
(14)
No comments:
Post a Comment